Mr. Farris Smith reports

HARMONY RECEIVES TSXV CONDITIONAL APPROVAL & FILES FILING STATEMENT REGARDING QUALIFYING TRANSACTION WITH VIMY PHARMA

Vimy Pharmaceuticals Inc. and Harmony Acquisitions Corp. have received conditional approval from the TSX Venture Exchange for Harmony's previously announced qualifying transaction (as such term is defined in TSX-V Policy 2.4 (Capital Pool Companies)). The proposed business combination transaction will be completed pursuant to the terms and conditions of the previously announced definitive agreement.

Pursuant to the definitive agreement, Harmony will acquire all the issued and outstanding shares of Vimy Pharma by way of a three-cornered amalgamation among Harmony, the company and a wholly owned subsidiary of Harmony incorporated for the purposes of completing the transaction. Upon completion of the transaction, Harmony (as it will exist following completion of the transaction) is expected to be listed on the TSX-V under the name Vimy Pharmaceuticals Corp. and under the ticker symbol VIMY.

For further information, please see Harmony's filing statement, which was filed on Nov. 6, 2026, and is available for review under Harmony's profile on SEDAR+. Closing of the transaction is expected to occur on or about Nov. 12, 2026. The completion of the transaction is subject to a number of conditions, including, but not limited to, receipt of all required regulatory, including final TSX-V acceptance and satisfaction of other customary closing conditions.

About Vimy Pharmaceuticals Inc.

Vimy Pharma is a Canadian pharmaceutical company focused on improving access to affordable medicines while supporting domestic pharmaceutical manufacturing capacity and long-term Canadian supply resilience. Vimy Pharma is advancing a portfolio of essential medicines as generic pharmaceutical products intended to support patients, health care systems and Canada's life science sector.

A strategic priority for the company is expanding access to therapies through the development of generic alternatives to popular medicines. By combining domestic production with cost-efficient manufacturing and regulatory expertise, Vimy Pharma seeks to provide affordable treatment options while contributing to Canada's pharmaceutical sovereignty.

Earlier this year, Vimy Pharma completed one of its development programs and filed an abbreviated new drug submission with Health Canada, which has been found acceptable for review, for a generic version of Ozempic (semaglutide injection), a glucagon-like peptide-1 receptor agonist indicated for the treatment of Type 2 diabetes. Vimy Pharma has also filed an ANDS with Health Canada for a generic version of Wegovy (semaglutide injection), a GLP-1 receptor agonist indicated for weight management. Ozempic has been the highest-earning prescription medicine in Canada for the past four years with combined sales of semaglutide injection medicines in Canada totalling $3.5-billion in 2025, growing at 31 per cent over the previous year. Vimy Pharma undertook its development work in Canada and will carry out its commercial production domestically, with Canadian partners. Additionally, Vimy Pharma has established partnerships to support the many large and growing international markets for injectable semaglutide.

Vimy Pharma is led by an experienced management team, including former executives from Novo Nordisk, with broader organizational expertise spanning pharmaceutical development, manufacturing, regulatory affairs, commercialization and capital markets. Vimy Pharma is committed to long-term value creation through disciplined execution, innovation and the development of a sustainable domestic pharmaceutical ecosystem that serves patients, health care providers and government partners, and supports Canadian pharmaceutical supply resilience and access to medicines.

About Harmony Acquisitions Corp.

Harmony was incorporated under the Business Corporations Act (British Columbia) on May 7, 2021, and is a capital pool company listed on the TSX-V.

We seek Safe Harbor.